JCB, Volume 20, Number 2, 2014 Editorial Vol.20 No. 2 (2014) Building biotechnology in India – Drugs are not the answer Yali Friedman Ihave had the pleasure of participating in national forums on biotechnology development in diverse countries. A common theme I see is that emerging economies wish to develop ‘a biot Article Vol.20 No. 2 (2014) Fostering technology transfer in industrial biotechnology by academic spin-offs Gunter Festel Article Vol.20 No. 2 (2014) Pharmaceutical R&D Productivity: The Role of Alliance Sarah Kruse In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect Article Vol.20 No. 2 (2014) Deciding between biobetter versus biosimilar development options based on net present value calculations Kerstin Marie Bode-Greuel  AbstractThe growing share of biopharmaceuticals is paralleled by an increasing interest in biogenerics, as blockbuster b Article Vol.20 No. 2 (2014) Market Orientation, Alliance Orientation, and Business Performance in the Biotechnology Industry Grant Alexander Wilson The purpose of this study was to test the unexplored relationship between market orientation (MO), alliance orientation (AO), and business performance (PERF) in the medical/healthcare sub From the Classroom Vol.20 No. 2 (2014) Bioentrepreneurship Education and Training Trends Arlen Meyers Biomedical and health entrepreneurship continues to expand around the world. Driven by global pressures to optimize the allocation of scarce resources, Intellectual Property Management Vol.20 No. 2 (2014) Where is the eBay for Intellectual Property? Matthew B Klusas This paper is an examination of the economics, organizational dynamics and structural factors inhibiting an electronic market for intellectual property.  Several intermediaries exist to f From the Boardroom Vol.20 No. 2 (2014) Biotech IPOs Steam Ahead in 2014 G. Steven Burrill If you walk into most private biotech company boardrooms today, it is likely that you will hear a discussion about whether to go public. Companies at every stage of development are either ge From the Boardroom Vol.20 No. 2 (2014) Considerations for Start-Up Biotech Company Valuation Walter Bratic The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, t From the Boardroom Vol.20 No. 2 (2014) Canadian Venture Capital - Unlocking the Funding Challenge Christopher H. Jones Canada plays a significant role in the global advancement of scientific discoveries and their translation into commercial opportunities, but is viewed as not fully realizing its commercia Book Review Vol.20 No. 2 (2014) New Books Yali Friedman New books from the publisher of the Journal of CommercialBiotechnology
